Prospective, multi-center, non-randomized, open label, clinical study intended to provide data to demonstrate safety and performance of the SoundBite Crossing System XS Peripheral.
The CaTO-PAD study includes a below-the-knee (BTK) sub-study (CaTO-BTK)
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
130
Use of the SoundBite Crossing System to cross calcified chronic total occlusions
Palm Vascular Centers
Fort Lauderdale, Florida, United States
RECRUITINGUNC REX Hospial
Raleigh, North Carolina, United States
NOT_YET_RECRUITINGLifespan - The Miriam Hospital
Providence, Rhode Island, United States
RECRUITINGDevice Performance
Crossing of the lesion regardless of method or modality (e.g., antegrade or retrograde)
Time frame: Day 0
Device Safety
Procedural incidence of any of the following: no reflow, thrombus formation, abrupt closure, distal embolization, dissection or perforation requiring treatment
Time frame: Day 0
Antegrade Crossing
Placement of a guidewire distal to the lesion in the true lumen (Note: retrograde crossing is allowed, but is considered a failure for this endpoint)
Time frame: Day 0
CTO Crossing Time
From first engagement of proximal cap with the Active Wire to guidewire in distal true lumen (or decision made to discontinue attempts)
Time frame: Day 0
Acute Lumen Gain
Difference in final minimal lumen diameter compared to baseline
Time frame: Day 0
Residual Percent Stenosis
Final percent stenosis at procedure end
Time frame: Day 0
Procedure Time
First groin puncture to final sheath removal
Time frame: Day 0
Fluoroscopy Time
Time frame: Day 0
Number of Devices Used
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Medizinische Universität Graz
Graz, Austria
NOT_YET_RECRUITINGAngiology Clinic and Vascular Centre
Arnsberg, Germany
NOT_YET_RECRUITINGConventional guidewires, microcatheters, atherectomy devices, re-entry devices, balloons, stents
Time frame: Day 0
Secondary Safety Endpoint
Rate of 30-day major adverse events (MAE) consisting of: death, emergency surgical revascularization of the target limb, unplanned amputation of the target limb, symptomatic distal thrombus or emboli requiring intervention, perforation requiring treatment
Time frame: Day 30 (+10/-0 days)